Return to homepagePandemic Pact

The impact of life-support on COVID-19 drugs

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    RBWH Foundation

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Does ECMO (Extracorporeal membrane oxygenation) life support for breathing and heart assistance in coronavirus patients, affect the dosage of COVID-19 drugs? Some COVID-19 patients develop severe respiratory, or cardiorespiratory failure, requiring ECMO support for heart and breathing assistance. Some types of drugs are vulnerable to loss during ECMO therapy. This research project will investigate whether the main COVID-19 drugs (chloroquine, hydroxychloroquine, lopinavir-ritonavir and remdesivir) are vulnerable to drug loss during ECMO therapy. This may help explain the high mortality (approximately 50%) in this patient sub-group. This research aims to confirm the amount of drug loss during ECMO therapy and establish new dosing recommendations.